Top

Published in:

01-06-2019 | Alzheimer's Disease | Original Article

Irisin and BDNF serum levels and behavioral disturbances in Alzheimer’s disease

Authors: Elisa Conti, Denise Grana, Giovanni Stefanoni, Alberto Corsini, Margherita Botta, Paolo Magni, Angelo Aliprandi, Christian Lunetta, Ildebrando Appollonio, Carlo Ferrarese, Lucio Tremolizzo

Published in: Neurological Sciences | Issue 6/2019

Abstract

Behavioral dysfunctions (BPSD) represent the most important problem in Alzheimer’s dementia (AD) management. We assessed the serum levels of two myokines in AD patients, preliminary investigating, as secondary aim, their role as potential biomarkers for agitation/aggression (AA) and aberrant motor behavior (AMB): irisin, since it is able to modify the motor pattern, and BDNF, since it was transcribed following irisin stimulation. Forty AD patients were recruited and characterized according to the expressed neuropsychiatric syndrome. Myokines were measured by ELISA. Irisin serum levels were slightly elevated in AA+ patients (+ 10.0%; p < 0.05) and correlated with the duration of AA (r = 0.74, p < 0.03). BDNF failed to show such differences. We propose that these selected myokines are not useful as surrogate markers for agitation in AD, but might represent interesting secondary outcomes when testing drugs for those BPSD implying elevated motor activity.

Zdanys KF, Carvalho AF, Tampi RR, Steffens DC (2016) The treatment of behavioral and psychological symptoms of dementia: weighing benefits and risks. Curr Alzheimer Res 13:1124–1133CrossRefPubMed

Tremolizzo L, Tironi M, Ferrarese C, Appollonio I (2013) Neuroleptic equivalent dose differences and behavioral and psychological symptoms of dementia. Dement Geriatr Cogn Disord 35:118–120CrossRefPubMed

Bloniecki V, Aarsland D, Cummings J, Blennow K, Freund-Levi Y (2014) Agitation in dementia: relation to core cerebrospinal fluid biomarker levels. Dement Geriatr Cogn Dis Extra 4:335–343CrossRefPubMedPubMedCentral

Mintzer J, Brawman-Mintzer O, Mirski DF, Unger R, Nietert P, Meeks A, Sampson R (1998) Fenfluramine challenge test as a marker of serotonin activity in patients with Alzheimer's dementia and agitation. Biol Psychiatry 44:918–921CrossRefPubMed

Higuchi M, Hatta K, Honma T, Hitomi YH, Kambayashi Y, Hibino Y, Matsuzaki I, Sasahara S, Nakamura H (2010) Association between altered systemic inflammatory interleukin-1beta and natural killer cell activity and subsequently agitation in patients with Alzheimer disease. Int J Geriatr Psychiatry 25:604–611PubMed

Zhang W, Chang L, Zhang C, Zhang R, Li Z, Chai B, Li J, Chen E, Mulholland M (2015) Irisin: a myokine with locomotor activity. Neurosci Lett 595:7–11CrossRefPubMedPubMedCentral

Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF (2013) Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity - correlation with body mass index. Peptides 39:125–130CrossRefPubMed

Jodeiri Farshbaf M, Ghaedi K, Megraw TL, Curtiss J, Shirani Faradonbeh M, Vaziri P, Nasr-Esfahani MH (2016) Does PGC1α/FNDC5/BDNF elicit the beneficial effects of exercise on neurodegenerative disorders? NeuroMolecular Med 18:1–15CrossRefPubMed

Kim OY, Song J (2018) The role of irisin in Alzheimer's disease. J Clin Med 7:E407CrossRefPubMed

10.

Weinstein G, Beiser AS, Choi SH, Preis SR, Chen TC, Vorgas D, Au R, Pikula A, Wolf PA, DeStefano AL, Vasan RS, Seshadri S (2014) Serum brain-derived neurotrophic factor and the risk for dementia: the Framingham Heart Study. JAMA Neurol 71:55–61CrossRefPubMedPubMedCentral

11.

Küster OC, Laptinskaya D, Fissler P, Schnack C, Zügel M, Nold V, Thurm F, Pleiner S, Karabatsiakis A, von Einem B, Weydt P, Liesener A, Borta A, Woll A, Hengerer B, Kolassa IT, von Arnim CAF (2017) Novel blood-based biomarkers of cognition, stress, and physical or cognitive training in older adults at risk of dementia: preliminary evidence for a role of BDNF, irisin, and the kynurenine pathway. J Alzheimers Dis 59:1097–1111CrossRefPubMed

12.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34:939–944CrossRefPubMed

13.

Spalletta G, Musicco M, Padovani A, Rozzini L, Perri R, Fadda L, Canonico V, Trequattrini A, Pettenati C, Caltagirone C, Palmer K (2010) Neuropsychiatric symptoms and syndromes in a large cohort of newly diagnosed, untreated patients with Alzheimer disease. Am J Geriatr Psychiatry 18:1026–1035CrossRefPubMed

14.

van der Flier WM, Staekenborg S, Pijnenburg YA, Gillissen F, Romkes R, Kok A, Bouwman FH, Scheltens P (2007) Apolipoprotein E genotype influences presence and severity of delusions and aggressive behavior in Alzheimer disease. Dement Geriatr Cogn Disord 23:42–46CrossRefPubMed

15.

Conti E, Tremolizzo L, Santarone ME, Tironi M, Radice I, Zoia CP, Aliprandi A, Salmaggi A, Dominici R, Casati M, Appollonio I, Ferrarese C (2016) Donepezil modulates the endogenous immune response: implications for Alzheimer's disease. Hum Psychopharmacol 31:296–303CrossRefPubMed

16.

Tremolizzo L, Pellegrini A, Conti E, Arosio A, Gerardi F, Lunetta C, Magni P, Appollonio I, Ferrarese C (2016) BDNF serum levels with respect to multidimensional assessment in amyotrophic lateral sclerosis. Neurodegener Dis 16:192–198CrossRefPubMed

17.

Nagels G, Engelborghs S, Vloeberghs E, Van Dam D, Pickut BA, De Deyn PP (2006) Actigraphic measurement of agitated behaviour in dementia. Int J Geriatr Psychiatry 21:388–393CrossRefPubMed

18.

Mahlberg R, Walther S (2007) Actigraphy in agitated patients with dementia. Monitoring treatment outcomes. Z Gerontol Geriatr 40:178–184CrossRefPubMed

19.

Phillips C, Baktir MA, Srivatsan M, Salehi A (2014) Neuroprotective effects of physical activity on the brain: a closer look at trophic factor signaling. Front Cell Neurosci 8:170CrossRefPubMedPubMedCentral

20.

Arosio A, Sala G, Rodriguez-Menendez V, Grana D, Gerardi F, Lunetta C, Ferrarese C, Tremolizzo L (2016) MEF2D and MEF2C pathways disruption in sporadic and familial ALS patients. Mol Cell Neurosci 74:10–17CrossRefPubMed

21.

Lunetta C, Lizio A, Tremolizzo L, Ruscica M, Macchi C, Riva N, Weydt P, Corradi E, Magni P, Sansone V (2018) Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status. J Neurol 265:3001–3008CrossRefPubMed

Title: Irisin and BDNF serum levels and behavioral disturbances in Alzheimer’s disease
Authors: Elisa Conti
Denise Grana
Giovanni Stefanoni
Alberto Corsini
Margherita Botta
Paolo Magni
Angelo Aliprandi
Christian Lunetta
Ildebrando Appollonio
Carlo Ferrarese
Lucio Tremolizzo
Publication date: 01-06-2019
Publisher: Springer International Publishing
Keywords: Alzheimer's Disease
Alzheimer's Disease
Agitation
Published in: Neurological Sciences / Issue 6/2019
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-019-03781-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Irisin and BDNF serum levels and behavioral disturbances in Alzheimer’s disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2019

A novel SLC20A2 gene mutation causing primary familial brain calcification in an Ukrainian patient

A novel mutation in the CSF1R gene causes hereditary diffuse leukoencephalopathy with axonal spheroids

New insights into the role of neuron-specific enolase in tic disorders

Cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies: a case report

The effect of dopamine for focal hand dystonia after stroke

Accuracy of MDS-UPDRS section IV for detecting motor fluctuations in Parkinson’s disease